Mumbai :  Jubilant Biosys , a Bengaluru-based subsidiary of Jubilant Life Sciences, today announced the USFDA acceptance of The Investigational New Drug (IND) filing for a novel molecule targeting prostate cancer. This molecule will now progress towards the next phase of development and is anticipated to go into clinical trials by late 2013, a company statement said … Continue reading Jubilant Biosys announces filing of Investigational New Drug